Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 246

Similar articles for PubMed (Select 22890323)

1.

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.

Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Barón AE, Franklin WA, Merrick DT, Jedlicka P, DeRyckere D, Heasley LE, Graham DK.

Oncogene. 2013 Jul 18;32(29):3420-31. doi: 10.1038/onc.2012.355. Epub 2012 Aug 13.

2.

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Linger RM, Keating AK, Earp HS, Graham DK.

Expert Opin Ther Targets. 2010 Oct;14(10):1073-90. doi: 10.1517/14728222.2010.515980. Review.

3.

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.

Wang Y, Xia H, Zhuang Z, Miao L, Chen X, Cai H.

Cell Death Dis. 2014 May 15;5:e1227. doi: 10.1038/cddis.2014.186.

4.

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG.

Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330.

5.

Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.

Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM.

Cancer Res. 2002 Jun 15;62(12):3530-7.

6.

Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.

Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK.

Mol Cancer Ther. 2010 May;9(5):1298-307. doi: 10.1158/1535-7163.MCT-09-0707. Epub 2010 Apr 27.

7.

Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma.

Li Y, Wang X, Bi S, Zhao K, Yu C.

Biochem Biophys Res Commun. 2015 Feb 13;457(3):461-6. doi: 10.1016/j.bbrc.2015.01.017. Epub 2015 Jan 14.

PMID:
25596315
8.

AXL mediates resistance to cetuximab therapy.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL.

Cancer Res. 2014 Sep 15;74(18):5152-64. doi: 10.1158/0008-5472.CAN-14-0294. Epub 2014 Aug 18.

PMID:
25136066
9.

Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.

Song L, Xiong H, Li J, Liao W, Wang L, Wu J, Li M.

Clin Cancer Res. 2011 Apr 1;17(7):1839-49. doi: 10.1158/1078-0432.CCR-10-0720. Epub 2011 Feb 15.

10.

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.

Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20.

11.

High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors.

Tang H, Yang J, Shen DR, Calambur D, Witmer M, Wu S, Carpenter B, Zhang Y, Gao M, Constantine K, Zhang L, Cvijic ME.

Assay Drug Dev Technol. 2014 Jan-Feb;12(1):80-6. doi: 10.1089/adt.2013.540.

PMID:
24547742
12.

Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion.

Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M.

Eur J Cancer. 2001 Nov;37(17):2264-74.

PMID:
11677117
13.

Targeting Axl and Mer kinases in cancer.

Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S.

Mol Cancer Ther. 2011 Oct;10(10):1763-73. doi: 10.1158/1535-7163.MCT-11-0116. Epub 2011 Sep 20. Review.

14.

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.

Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.

Mol Cancer Ther. 2009 Dec;8(12):3296-306. doi: 10.1158/1535-7163.MCT-09-0538. Epub .

15.

Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.

Liu R, Gong M, Li X, Zhou Y, Gao W, Tulpule A, Chaudhary PM, Jung J, Gill PS.

Blood. 2010 Jul 15;116(2):297-305. doi: 10.1182/blood-2009-12-257154. Epub 2010 May 4.

16.

TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.

Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT.

Cancer Res. 2013 Nov 1;73(21):6516-25. doi: 10.1158/0008-5472.CAN-13-0967. Epub 2013 Sep 6.

17.

Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.

Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE.

Cancer Res. 2007 Apr 15;67(8):3878-87.

18.

Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.

PLoS One. 2011;6(8):e23756. doi: 10.1371/journal.pone.0023756. Epub 2011 Aug 17.

19.

Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer.

Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, Franco R, Melillo RM.

Cancer Res. 2011 Mar 1;71(5):1792-804. doi: 10.1158/0008-5472.CAN-10-2186. Epub 2011 Feb 22.

20.

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis.

Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ, Pei L.

Oncogene. 2009 Oct 1;28(39):3442-55. doi: 10.1038/onc.2009.212. Epub 2009 Jul 27.

PMID:
19633687
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk